Harm de Vries

Erasmus Medical Center (Private Equity) (Erasmus MC-PE) is the private equity division of Erasmus MC in The Netherlands. Established in 1998 as the Erasmus Medical Centerby the Dean of the faculty and the Boards of the Erasmus University Rotterdam, they became Erasmus MC in 2002. The Erasmus MC Biomedical Fund BV investment team is based in Rotterdam, and invests in seed and early-stage firms in the life science sector.

Acaros BV develops therapies and biomarkers for bone diseases. The company was founded in 2008 and is headquartered in Rotterdam, the Netherlands.

Arcarios BV discovers and develops innovative products for bone and joint diseases. The company is headquartered in Rotterdam, Netherlands.

Cavadis BV discovers biomarkers for progression of atherosclerotic disease. The firm’s product series include pipeline, medical need, market potential and personalized medicine. The company was founded in 2007 by Ronald Nanninga and Oscar Schoots and is headquartered in Hilversum, the Netherlands.

ACS Biomarker BV develops and commercializes cardiovascular biomarkers. The firm offers miRNA profiling services. It engages in the discovery, validation, and commercialization of biomarkers that improve diagnosis, prognosis and management of cardiac diseases. The company was founded in 2007 by Mat J. A. P. Daemen, Yigal M. Pinto and Tilman Hackeng and is headquartered in Maastricht, the Netherlands.

Encapson BV operates as a medical device technology company. It specializes in the use of polymer-based capsules for microencapsulation. The company's products include Capsol, a paclitaxol delivery method for drug eluting balloons; and Sono-coat, an echogenic coating that is applied for biopsy and anesthesiology needles, brachytherapy needles, guiding and embryo transfer catheters, and drainage catheters. Encapson was founded by Lee Ayres and Dennis Manuel Vriezema in 2005 and is headquartered in Enschede, the Netherlands.

MirNext BV focuses on the discovery, validation and commercialization of microRNAs as novel biomarkers for cardiovascular disease. Its multiple circulating miRNAs act as informative markers for the diagnosis of heart failure, coronary artery disease, and myocardial infarction, as well as used to predict cardiovascular risk, such as mortality and hospitalization. The company was founded in 2012 and is headquartered in Amsterdam, the Netherlands.